Pacira BioSciences, Inc. (PCRX) — Stock Score Summary

Pacira BioSciences, Inc. (PCRX) has a MoatMap StockRank of 85/100 based on Quality (60/100), Value (49/100), and Momentum (60/100) factor scores. The current signal is STRONG BUY. Pacira BioSciences faces generic competition for its flagship product Exparel, violating our core requirement for a durable, un-copyable economic moat.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing, commercializing, and manufacturing non-opioid pain management products, with its flagship EXPAREL providing long-acting local analgesia for postsurgical pain. The company benefits from its proprietary drug delivery technology, DepoFoam, and the strong market position of EXPAREL as a leading non-opioid solution, creating a significant competitive moat in the growing demand for opioid alternatives.

Key Financial Metrics

Price$22.32
Market Cap$932M
P/E (TTM)187.38
P/E (Forward)6.69
Price/Book1.46
Return on Equity0.7%
Return on Invested Capital2.8%
Debt/Equity62.88
Gross Margin79.3%
Operating Margin2.6%
Revenue Growth5.0%
Free Cash Flow$99M

Pacira BioSciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Pacira BioSciences, Inc.’s (PCRX) StockRank?
MoatMap’s StockRank for Pacira BioSciences, Inc. (PCRX) is 85/100, with a Strong Buy signal. It is a composite of Quality (60), Value (49), and Momentum (60) factor ranks across MoatMap’s 19,000+ stock universe.
Does Pacira BioSciences, Inc. have an economic moat?
Pacira BioSciences, Inc. (PCRX) has a Quality factor score of 60/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pacira BioSciences, Inc. a buy, hold, or sell?
MoatMap’s current signal for Pacira BioSciences, Inc. (PCRX) is Strong Buy, based on a StockRank of 85/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Pacira BioSciences, Inc. in?
Pacira BioSciences, Inc. (PCRX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksPCRX deep dive reportAI ChampionsHow we score stocksSense-check another stock